NCT04757272

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019 (COVID-19)?

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,106 (actual)
• Sponsor: Zagazig University · Other Government
• Sex: All
• Age: 21 Years – 80 Years
• Healthy volunteers: —

Summary

Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.

Detailed description

The interaction of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the renin angiotensin system (RAS) via angiotensin converting enzyme-2 (ACE-2), the receptor used by the SARS-CoV-2 to gain access to cells could provide an explanation for the several unusual clinical findings observed in COVID-19 Although chronic hepatitis is one of the risk factors listed by WHO for severe COVID-19, low incidence of COVID-19 was observed among HCV patients admitted to Egyptian hospitals. Modulation of the RAS by the chronic hepatitis C virus treatment either by (ACEI or ARBS), (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.

Conditions

• Corona Virus Infection
• Hepatitis

Timeline

• Start date: 2020-05-01
• Primary completion: 2022-03-30
• Completion: 2022-07-30
• First posted: 2021-02-17
• Last updated: 2022-09-30

Locations

1 site across 1 country: Egypt